Pasithea Therapeutics Confirms Nasdaq Listing in 8-K Filing
Ticker: KTTAW · Form: 8-K · Filed: Jan 18, 2024 · CIK: 1841330
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, exchange-listing, other-events
TL;DR
**KTTA filed an 8-K confirming Nasdaq listing, but the 'Other Event' is a mystery.**
AI Summary
Pasithea Therapeutics Corp. (KTTA) filed an 8-K on January 18, 2024, reporting an 'Other Event' that occurred on January 17, 2024. While the filing itself is brief and doesn't detail the specific event, it confirms the company's common stock and warrants are registered on The Nasdaq Capital Market. This matters to investors because it reaffirms KTTA's listing status, which is crucial for liquidity and visibility, though the lack of detail on the 'Other Event' means investors should watch for further disclosures.
Why It Matters
This filing confirms Pasithea Therapeutics' continued listing on The Nasdaq Capital Market, which is important for the stock's trading liquidity and investor confidence. The 'Other Event' mentioned, without detail, suggests investors should monitor for subsequent announcements.
Risk Assessment
Risk Level: medium — The risk is medium because while the Nasdaq listing is confirmed, the unspecified 'Other Event' could be significant and warrants further investigation by investors.
Analyst Insight
A smart investor would monitor Pasithea Therapeutics Corp.'s subsequent filings and news releases closely for details regarding the unspecified 'Other Event' to assess any potential impact on the company's operations or stock price, while acknowledging the confirmed Nasdaq listing provides stability.
Key Numbers
- $0.0001 — Par Value per Share (This is the stated par value for both the common stock and warrants of Pasithea Therapeutics Corp.)
Key Players & Entities
- Pasithea Therapeutics Corp. (company) — the registrant filing the 8-K
- The Nasdaq Capital Market (company) — the exchange where KTTA's securities are registered
- $0.0001 (dollar_amount) — par value per share of common stock and warrants
- January 17, 2024 (date) — date of the earliest event reported
- January 18, 2024 (date) — date the 8-K was filed
Forward-Looking Statements
- Pasithea Therapeutics Corp. will issue a follow-up filing or press release detailing the 'Other Event' reported on January 17, 2024. (Pasithea Therapeutics Corp.) — medium confidence, target: 2024-02-17
FAQ
What was the specific 'Other Event' reported by Pasithea Therapeutics Corp. on January 17, 2024?
The 8-K filing states the 'Date of earliest event reported' as January 17, 2024, under 'ITEM INFORMATION: Other Events,' but it does not provide any specific details about what this 'Other Event' entails. Investors would need to look for subsequent filings or press releases for clarification.
On which exchange are Pasithea Therapeutics Corp.'s securities registered?
Pasithea Therapeutics Corp.'s Common Stock, par value $0.0001 per share, and Warrants to purchase shares of Common Stock, par value $0.0001 per share, are registered on The Nasdaq Capital Market, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.
What is the par value of Pasithea Therapeutics Corp.'s common stock and warrants?
Both the Common Stock and Warrants to purchase shares of Common Stock of Pasithea Therapeutics Corp. have a par value of $0.0001 per share, according to the filing.
When was this 8-K filing submitted to the SEC?
The 8-K filing was filed as of January 18, 2024, as indicated by the 'FILED AS OF DATE' in the header information.
What is the trading symbol for Pasithea Therapeutics Corp.'s common stock?
The trading symbol for Pasithea Therapeutics Corp.'s Common Stock, par value $0.0001 per share, is KTTA, as listed under 'Title of each class' and 'Trading Symbol(s)' in the filing.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-01-18 16:30:41
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share KTTA The Nasdaq Capital M
- $1.00 m — Company was not in compliance with the $1.00 minimum bid price requirement, as set for
- $1.00 — ntained a closing bid price at or above $1.00 per share for a sufficient number of co
Filing Documents
- ea191820-8k_pasithea.htm (8-K) — 27KB
- 0001213900-24-004520.txt ( ) — 241KB
- ktta-20240117.xsd (EX-101.SCH) — 4KB
- ktta-20240117_def.xml (EX-101.DEF) — 26KB
- ktta-20240117_lab.xml (EX-101.LAB) — 36KB
- ktta-20240117_pre.xml (EX-101.PRE) — 25KB
- ea191820-8k_pasithea_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events As previously reported, on January 19, 2023, Pasithea Therapeutics Corp. (the "Company") received a notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that the Company was not in compliance with the $1.00 minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2), and on July 19, 2023, the Company received a subsequent notice extending the deadline to regain compliance to January 15, 2024. On January 17, 2024, the Company received a letter from Nasdaq stating that the Common Stock had maintained a closing bid price at or above $1.00 per share for a sufficient number of consecutive business days to regain compliance with the minimum bid price requirement, and that the matter is now closed. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASITHEA THERAPEUTICS CORP. Dated: January 18, 2024 By: /s/ Tiago Reis Marques Name: Tiago Reis Marques Title: Chief Executive Officer 2